LGCI-Yamanouchi Cooperation for Medicine Development

Published: 2001-11-07 06:57:00

Updated: 2001-11-07 06:57:00

LGCI announced on November 2 that they have forged a strategic cooperation agreement with Yamanouchi, the third ranking pharmaceutical company in Japan, to develop new medicine for corpulence and hyperlipemia.

According to the agreement, LGCI and Yamanouchi will carry out joint research projec...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK